RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (AMEX:ISR) a medical isotope company focusing on the treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, announced its financial results for the quarter and six months ended December 31, 2007.
